MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$3.95 -0.51%

-$0.02 today

Market cap
$1.27B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 4.08M

Average 5.73M

Returns on capital

MannKind Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-11.5%

avg 21.1%

ROIC

5.8%

avg -6.8%

ROA

0.7%

avg -50.1%

Analysis

ROIC is currently the strongest return metric at 5.8% versus its period average of -6.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael E. Castagna

Chief Executive Officer & DirectorUSD 1.61M50——

David Thomson

Executive Vice President, General Counsel & SecretaryUSD 1.02M59797.55K0.26%

Stuart A. Tross

Chief People & Workplace OfficerUSD 812.22K590<0.01%

Christopher Prentiss

Chief Financial OfficerUSD 753.32K51——

Dominic Marasco

President of Endocrine Business UnitUSD 717.72K54343.40K0.11%

Sanjay Singh

Executive Vice President of Technical OperationsUSD 364.53K60——

Ajay Ahuja

Executive VP & Chief Medical Officer—56217.00K0.07%

Wassim Fares

Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$259,000.00

Sells

12

$3.04M

Net Transaction Value

−$2.78M

Net selling

Most Active

Binder Steven B.

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 25, 26

Binder Steven B.

Direct

Sell$128.5K
Sep 10, 26

Binder Steven B.

Direct

Sell$127.9K
Aug 7, 26

Binder Steven B.

Direct

Sell$158.5K
Jul 17, 26

Thomson David

Direct

Sell$97.6K
Jul 17, 26

Binder Steven B.

Direct

Sell$213.1K
May 12, 26

Binder Steven B.

Direct

Sell$55.7K
May 12, 26

Thomson David

Direct

Sell$10K
Mar 10, 26

Castagna Michael

Direct

Buy$259K
Jan 8, 26

Tross Stuart A

Direct

Sell$297.5K
Dec 17, 25

Castagna Michael

Direct

Sell$395.5K

1–10 of 13

Summary

Insiders reported 1 buys worth $259,000.00 and 12 sells worth $3.04M over the last 12 months. That adds up to net selling of $2.78M. Binder Steven B. was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+79.2% (5yr)5 analysts
RevenueN/AN/A+51.8%
+13.8% (5yr)6 analysts
Net IncomeN/AN/AN/A
+81.7% (5yr)6 analysts
EBITN/AN/AN/A
+34.8% (5yr)6 analysts

Analysis

Recent growth has been strongest in Revenue at +51.8% over three years. Forward estimates point to Net Income at +81.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does MannKind Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MNKD's management, answered from reported figures.

Who manages MNKD?

MannKind Corporation (MNKD) lists 8 active executives. The top listed executive is Ajay Ahuja, Executive VP & Chief Medical Officer.

Are MNKD insiders buying or selling?

Recent insider activity shows net selling of $8.72M.